Long-term effects of the iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients

Abstract

The serum phosphorus-lowering effect of sucroferric oxyhydroxide was maintained over 1 year and associated with a lower pill burden, compared with sevelamer. Sucroferric oxyhydroxide was generally well tolerated long-term and there was no evidence of iron accumulation.